Lester Crawford
FameRank: 3

"Lester Mills Crawford" is an United States/American veterinarian and Commissioner of Food and Drugs/Commissioner of the US Food and Drug Administration who was appointed by George W. Bush. He served from July 18, 2005 until resigning two months later in September 2005.

On October 17, 2006, he Plea/pled guilty to a conflict of interest and false reporting of information about stocks he owned in food, beverage and medical device companies he was in charge of regulating. [http://www.washingtonpost.com/wp-dyn/content/article/2006/10/17/AR2006101700573.html] He received a Sentence (law)/sentence of three years of supervised probation and a fine (penalty)/fine of about $90,000. [http://www.washingtonpost.com/wp-dyn/content/article/2007/02/27/AR2007022701521.html]

More Lester Crawford on Wikipedia.

Talented and smart, and I am delighted to have been able to recruit him back to the agency to help me fulfill our public-health goals.

264

Previous shortages highlighted the need for additional influenza vaccine manufacturers for the U.S. market, ... Accelerated approval has allowed us to evaluate and approve Fluarix in record time so that we can make available additional safe and effective flu vaccines.

165

These are profound regulatory decisions.

153

Accelerated approval has allowed us to evaluate and approve Fluarix in record time so that we can make available additional safe and effective flu vaccines, ... I commend our Center for Biologics for taking extraordinary steps to help us be better prepared for both the upcoming and future flu seasons.

145

I also must thank the extraordinary people of FDA for the honor of having served with them, ... They have made public service a joy and a pleasure as we worked together to accomplish great things for public health.

131

Previous shortages highlighted the need for additional influenza vaccine manufacturers for the U.S. market.

114

There are unique regulatory issues that need to be addressed, ... We can only decide these issues in an open process. That will let us decide whether FDA can approve a drug for both over-the-counter and prescription use, for the same indication, sold in the same package.

111

I think we're going to come close to Canada at the end of the day.

100

[The issue has raised] many difficult and novel policy and regulatory issues, ... We need to resolve these policy and regulatory questions before we can reach a decision on the underlying science.

93